http://hl7.eu/fhir/ig/gravitate-health/Bundle/bundlepackageleaflet-en-proc-2f37d696067eeb6daf1111cfc3272672
type: Bundle
node role: treeRoot
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi
    l: Bundle-uv-epi
language:
  v: en
identifier:
  system:
    v: https://www.gravitatehealth.eu/sid/doc
    l: doc
  value:
    v: 39.955
type:
  v: document
timestamp:
  v: 2023-06-27T10:09:22Z
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Composition/composition-en-proc-ac2bb08bb4cc3f51f8c4e3513034c019
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-tegretol-carbamazepine
    l: ingredient-for-tegretol-carbamazepine
  resource: ingredient-for-tegretol-carbamazepine
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-tegretol-magnesiumstearate
    l: ingredient-for-tegretol-magnesiumstearate
  resource: ingredient-for-tegretol-magnesiumstearate
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-tegretol-carboxymethylcellulose
    l: ingredient-for-tegretol-carboxymethylcellulose
  resource: ingredient-for-tegretol-carboxymethylcellulose
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/SubstanceDefinition/substance-carbamazepine
    l: substance-carbamazepine
  resource: substance-carbamazepine
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/ap-2f37d696067eeb6daf1111cfc3272672
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/RegulatedAuthorization/authorization2f37d696067eeb6daf1111cfc32726720
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/Organization/mah-990eca26437774887062cfa11ea1d904
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-1618faf0346b4539ed1e3d6b23353e60
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/MedicinalProductDefinition/mpac2bb08bb4cc3f51f8c4e3513034c019
    l: mpac2bb08bb4cc3f51f8c4e3513034c019
  resource: mpac2bb08bb4cc3f51f8c4e3513034c019
entry:
  full url:
    v: http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/mid-2f37d696067eeb6daf1111cfc3272672

http://hl7.eu/fhir/ig/gravitate-health/Composition/composition-en-proc-ac2bb08bb4cc3f51f8c4e3513034c019
type: Composition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi
    l: Composition-uv-epi
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Composition composition-en-proc-ac2bb08bb4cc3f51f8c4e3513034c019 Language: en Profile: Composition (ePI) HtmlElementLink elementClass: indication concept: Trigeminal neuralgia (disorder) HtmlElementLink elementClass: pregnancyCategory concept: Pregnancy HtmlElementLink elementClass: contra-indication-hypericum concept: Hypericum perforatum L. HtmlElementLink elementClass: contra-indication-biktarvy concept: bictegravir identifier: https://spor.ema.europa.eu/rmswi//534a006e1f56f191eb76fdea4cfbf86d status: Final type: Package Leaflet category: processed date: 2022-02-16 13:28:17+0000 author: Organization Novartis Farmacéutica, S.A. title: TEST PURPOSES ONLY - Tegretol 200 mg tablets Attesters - Mode Time * Official 2022-02-16 13:28:17+0000
extension:
  extension:
    url:
      v: elementClass
      l: elementClass
    value: String
      v: indication
  extension:
    url:
      v: concept
      l: concept
    value: CodeableReference
      concept:
        coding: http://snomed.info/id/31681005
  url:
    v: http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink
    l: HtmlElementLink
extension:
  extension:
    url:
      v: elementClass
      l: elementClass
    value: String
      v: pregnancyCategory
  extension:
    url:
      v: concept
      l: concept
    value: CodeableReference
      concept:
        coding: http://snomed.info/id/69840006
  url:
    v: http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink
    l: HtmlElementLink
extension:
  extension:
    url:
      v: elementClass
      l: elementClass
    value: String
      v: contra-indication-hypericum
  extension:
    url:
      v: concept
      l: concept
    value: CodeableReference
  url:
    v: http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink
    l: HtmlElementLink
extension:
  extension:
    url:
      v: elementClass
      l: elementClass
    value: String
      v: contra-indication-biktarvy
  extension:
    url:
      v: concept
      l: concept
    value: CodeableReference
  url:
    v: http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink
    l: HtmlElementLink
identifier:
  system:
    v: https://spor.ema.europa.eu/rmswi/
    l: rmswi
status:
  v: final
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi/
      l: rmswi
    code:
      v: 100000155538
  text:
    v: Package Leaflet
category:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs
      l: epicategory-cs
    code:
      v: P
    display:
      v: processed
subject:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
date:
  v: 2022-02-16T13:28:17Z
title:
  v: TEST PURPOSES ONLY - Tegretol 200 mg tablets
attester:
  mode:
    coding:
      system:
        v: http://hl7.org/fhir/composition-attestation-mode
        l: composition-attestation-mode
      code:
        v: official
  time:
    v: 2022-02-16T13:28:17Z
section:
  title:
    v: B. Package Leaflet
  code:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi/
        l: rmswi
      code:
        v: 100000155538
    text:
      v: B. Package Leaflet
  text:
    status:
      v: additional
    div:
      v: unavailable
  empty reason:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/list-empty-reason
        l: list-empty-reason
      code:
        v: unavailable
  section:
    title:
      v: Package leaflet: Information for the user
    code:
      text:
        v: Package leaflet: Information for the user
    text:
      status:
        v: additional
      div:
        v: What Tegretol Tablets are and what they are used for What you need to know before you take Tegretol Tablets How to take Tegretol Tablets Possible side effects How to store Tegretol Tablets Contents of the pack and other information
  section:
    title:
      v: What is in this leaflet
    code:
      text:
        v: What is in this leaflet
    text:
      status:
        v: additional
      div:
        v: unavailable
  section:
    title:
      v: 1. What Tegretol 200 mg Tablets is and what it is used for
    code:
      text:
        v: 1. What Tegretol 200 mg Tablets is and what it is used for
    text:
      status:
        v: additional
      div:
        v: Carbamazepine, the active ingredient in Tegretol Tablets, can affect the body in several different ways. It is an anti-convulsant medicine (prevents fits), it can also modify some types of pain and can control mood disorders. Tegretol is used: To treat some forms of epilepsy To treat a painful condition of the face called trigeminal neuralgia To help control serious mood disorders when some other medicines don’t work
  section:
    title:
      v: 2. What you need to know before you take Tegretol 200 mg Tablets
    code:
      text:
        v: 2. What you need to know before you take Tegretol 200 mg Tablets
    text:
      status:
        v: additional
      div:
        v: Some people MUST NOT take Tegretol Tablets. Talk to your doctor if: you think you may be hypersensitive (allergic) to carbamazepine or similar drugs such as oxcarbazepine (Trileptal), or to any of a related group of drugs known as tricyclic antidepressants (such as amitriptyline or imipramine). If you are allergic to carbamazepine there is a one in four (25%) chance that you could also have an allergic reaction to oxcarbazepine. you think you may be allergic to any of the other ingredients of Tegretol Tablets (these are listed at the end of the leaflet). Signs of a hypersensitivity reaction include swelling of the face or mouth (angioedema), breathing problems, runny nose, skin rash, blistering or peeling. you have any heart problems, you have ever had problems with your bone marrow, you have a blood disorder called porphyria, you have taken drugs called monoamine oxidase inhibitors (MAOIs), used to treat depression, within the last 14 days. If any of these apply to you, do not take Tegretol and tell your doctor. A small number of people being treated with anti-epileptics such as carbamazepine have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor. If an allergic reaction happens, such as swelling of lips, eyelids, face, throat, mouth, or sudden breathing problems, fever with lymph nodes swelling, rash or skin blistering, tell your doctor immediately or go to the emergency department at your nearest hospital (see “Possible side effects”). Serious skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of carbamazepine. Frequently, the rash can involve ulcers of the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These serious skin rashes are often preceded by influenza-like symptoms fever, headache, body ache (flu-like symptoms). The rash may progress to widespread blistering and peeling of the skin. The highest risk for occurrenc…
  section:
    title:
      v: 3. How to take Tegretol 200 mg Tablets
    code:
      text:
        v: 3. How to take Tegretol 200 mg Tablets
    text:
      status:
        v: additional
      div:
        v: The doctor will tell you how many Tegretol Tablets to take and when to take them. Always follow his/her instructions carefully. The dose will be on the pharmacist’s label. Check the label carefully. It is important to take the tablets at the right times. If you are not sure, ask your doctor or pharmacist. Keep taking your tablets for as long as you have been told, unless you have any problems. In that case, check with your doctor. Your doctor will usually start Tegretol at a fairly low dose which can then be increased to suit you individually. The dose needed varies between patients. You can take Tegretol Tablets during, after or between meals. Swallow the tablets with a drink. You are usually told to take a dose two or three times a day. If necessary you may break the tablets in half along the scored line. To treat epilepsy the usual doses are: Adults: 800-1,200 mg a day, although higher doses may be necessary. If you are elderly you might require a lower dose. Children: Aged 5-10 years: 400-600 mg a day Aged 10-15 years: 600-1,000 mg a day. Tegretol Tablets are not recommended for children under 5. To treat trigeminal neuralgia the usual dose is: 600-800 mg a day. The maximum dose is 1200mg a day. If you are elderly you might require a lower dose. To treat mood swings the usual dose is: 400-600 mg a day What if you forget to take a dose? If you forget to take a dose, take one as soon as you remember. If it is nearly time for your next dose, though, just take the next dose and forget about the one you missed. What if you take too many tablets? If you accidentally take too many Tegretol Tablets, tell your doctor or your nearest hospital casualty department. Take your medicine pack with you so that people can see what you have taken.
  section:
    title:
      v: 4. Possible side effects
    code:
      text:
        v: 4. Possible side effects
    text:
      status:
        v: additional

ingredient-for-tegretol-carbamazepine
type: Ingredient
id:
  v: ingredient-for-tegretol-carbamazepine
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-tegretol-carbamazepine Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/33CM23913M (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#39955 (use: official, ); status = active; manufacturedDoseForm = Film-coated tablet; unitOfPresentation = Tablet MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/98/071/004; status = active; administrableDoseForm = tablet; unitOfPresentation = tablet role: active substance Codes - Concept * CARBAMAZEPINE Strengths - Presentation[x] Basis * 120 mg (Details: UCUM codemg = 'mg') active ingredient - basis of strength
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 33CM23913M
status:
  v: active
for:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 72072
    display:
      v: active
substance:
  strength:
    presentation: Quantity
      value:
        v: 120
      system:
        v: http://unitsofmeasure.org
        l: unitsofmeasure.org
      code:
        v: mg

ingredient-for-tegretol-magnesiumstearate
type: Ingredient
id:
  v: ingredient-for-tegretol-magnesiumstearate
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-tegretol-magnesiumstearate Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/70097M6I30 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#39955 (use: official, ); status = active; manufacturedDoseForm = Film-coated tablet; unitOfPresentation = Tablet MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/98/071/004; status = active; administrableDoseForm = tablet; unitOfPresentation = tablet role: Excipient substance Codes - Concept * Magnesium stearate
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 70097M6I30
status:
  v: active
for:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

ingredient-for-tegretol-carboxymethylcellulose
type: Ingredient
id:
  v: ingredient-for-tegretol-carboxymethylcellulose
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient ingredient-for-tegretol-carboxymethylcellulose Profile: Ingredient (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/05JZI7B19X (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#39955 (use: official, ); status = active; manufacturedDoseForm = Film-coated tablet; unitOfPresentation = Tablet MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription AdministrableProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/98/071/004; status = active; administrableDoseForm = tablet; unitOfPresentation = tablet role: Excipient substance Codes - Concept * CARBOXYMETHYLCELLULOSE
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 05JZI7B19X
status:
  v: active
for:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
role:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072082
    display:
      v: Excipient

substance-carbamazepine
type: SubstanceDefinition
id:
  v: substance-carbamazepine
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi
    l: SubstanceDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: SubstanceDefinition substance-carbamazepine Profile: SubstanceDefinition (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta//33CM23913M (use: official, ) version: 1 status: Active manufacturer: Organization Novartis Farmacéutica, S.A. MolecularWeights - Type Amount * exact 236.27 Structures - MolecularFormula * C15H12N2O Names - Name Type * 5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE Chemical Name
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta/
    l: beta
  value:
    v: 33CM23913M
version:
  v: 1
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
molecular weight:
  type:
    text:
      v: exact
  amount:
    value:
      v: 236.27
structure:
  molecular formula:
    v: C15H12N2O
name:
  name:
    v: 5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
  type:
    coding:
      system:
        v: https://gsrs.ncats.nih.gov/ginas/app/beta/
        l: beta
      code:
        v: x
      display:
        v: Chemical Name

http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/ap-2f37d696067eeb6daf1111cfc3272672
type: AdministrableProductDefinition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi
    l: AdministrableProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: AdministrableProductDefinition ap-2f37d696067eeb6daf1111cfc3272672 Profile: AdministrableProductDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/EU/1/98/071/004 status: Active formOf: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription administrableDoseForm: tablet unitOfPresentation: tablet producedFrom: ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#39955 (use: official, ); status = active; manufacturedDoseForm = Film-coated tablet; unitOfPresentation = Tablet routeOfAdministration code: Oral use TargetSpecies - Code * Human
identifier:
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: EU/1/98/071/004
status:
  v: active
form of:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
administrable dose form:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 200000002152
    display:
      v: tablet
unit of presentation:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 200000002152
    display:
      v: tablet
route of administration:
  code:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi
        l: rmswi
      code:
        v: 100000073619
      display:
        v: Oral use

http://hl7.eu/fhir/ig/gravitate-health/RegulatedAuthorization/authorization2f37d696067eeb6daf1111cfc32726720
type: RegulatedAuthorization
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi
    l: RegulatedAuthorization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: RegulatedAuthorization authorization2f37d696067eeb6daf1111cfc32726720 Profile: RegulatedAuthorization (ePI) identifier: https://spor.ema.europa.eu/pmswi/39.955 (use: official, ) subject: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription type: Marketing Authorisation status: Active statusDate: 2018-06-21 holder: Organization Novartis Farmacéutica, S.A.
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: 39.955
subject:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072062
    display:
      v: Marketing Authorisation
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2018-06-21

http://hl7.eu/fhir/ig/gravitate-health/Organization/mah-990eca26437774887062cfa11ea1d904
type: Organization
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization mah-990eca26437774887062cfa11ea1d904 Profile: Organization (ePI) identifier: https://spor.ema.europa.eu/omswi/ORG-100001650 (use: official, ) active: true type: Marketing authorisation holder name: Novartis Farmacéutica, S.A. Contacts - Address * Gran Via de les Corts Catalanes, 764 barcelona Spain(work)
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/omswi
    l: omswi
  value:
    v: ORG-100001650
active:
  v: true
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 220000000034
    display:
      v: Marketing authorisation holder
name:
  v: Novartis Farmacéutica, S.A.
contact:
  address:
    use:
      v: work
    type:
      v: physical
    text:
      v: Gran Via de les Corts Catalanes, 764 barcelona Spain
    line:
      v: Gran Via de les Corts Catalanes, 764
    city:
      v: barcelona
    postal code:
      v: 8013
    country:
      v: Spain

http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-1618faf0346b4539ed1e3d6b23353e60
type: PackagedProductDefinition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition ppd-1618faf0346b4539ed1e3d6b23353e60 Profile: PackagedProductDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/39.955 (use: official, ) name: Tegretol 200 mg tablets 28 type: Chemical Medicinal Prodcut packageFor: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription status: Active statusDate: 2012-02-07 13:28:17+0000 containedItemQuantity: 50 {tablets} (Details: UCUM code{tablets} = '{tablets}') packaging type: Box quantity: 1 material: Cardboard packaging identifier: https://spor.ema.europa.eu/pmswi/168740 type: Blister quantity: 28 material: PolyVinyl Chloride containedItem Items - Reference * ManufacturedItemDefinition: identifier = https://spor.ema.europa.eu/pmswi#39955 (use: official, ); status = active; manufacturedDoseForm = Film-coated tablet; unitOfPresentation = Tablet
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: 39.955
name:
  v: Tegretol 200 mg tablets 28
type:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000155527
    display:
      v: Chemical Medicinal Prodcut
package for:
  l: mpac2bb08bb4cc3f51f8c4e3513034c019
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2012-02-07T13:28:17Z
contained item quantity:
  value:
    v: 50
  system:
    v: http://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: {tablets}
packaging:
  type:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi
        l: rmswi
      code:
        v: 100000073498
      display:
        v: Box
  quantity:
    v: 1
  material:
    coding:
      system:
        v: https://spor.ema.europa.eu/rmswi
        l: rmswi
      code:
        v: 200000003529
      display:
        v: Cardboard
  packaging:
    identifier:
      system:
        v: https://spor.ema.europa.eu/pmswi
        l: pmswi
      value:
        v: 168740
    quantity:
      v: 28

mpac2bb08bb4cc3f51f8c4e3513034c019
type: MedicinalProductDefinition
id:
  v: mpac2bb08bb4cc3f51f8c4e3513034c019
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi
    l: MedicinalProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: MedicinalProductDefinition mpac2bb08bb4cc3f51f8c4e3513034c019 Profile: MedicinalProductDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/39.955, https://www.who-umc.org/phpid_4/FB9808F4FED210183F412F9998622287, https://www.who-umc.org/phpid_3/5C62673C79E096D37914D32A45AA8F4D type: Medicinal Product domain: Human use status: active legalStatusOfSupply: Medicinal product subject to medical prescription name productName: Tegretol 200 mg tablets type: Full name part part: Tegretol type: Invented name part part part: Carbamazepine type: Scientific name part part part: 200 mg type: Strength part part part: tablets type: Pharmaceutical dose form part Usages - Country Jurisdiction Language * Spain Spain English
identifier:
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: 39.955
identifier:
  system:
    v: https://www.who-umc.org/phpid_4
    l: phpid 4
identifier:
  system:
    v: https://www.who-umc.org/phpid_3
    l: phpid 3
type:
  coding:
    system:
      v: http://hl7.org/fhir/medicinal-product-type
      l: medicinal-product-type
    code:
      v: MedicinalProduct
    display:
      v: Medicinal Product
domain:
  coding:
    system:
      v: http://hl7.org/fhir/medicinal-product-domain
      l: medicinal-product-domain
    code:
      v: Human
    display:
      v: Human use
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: active
legal status of supply:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 100000072084
    display:
      v: Medicinal product subject to medical prescription
name:
  product name:
    v: Tegretol 200 mg tablets
  type:
    coding:
      system:
        v: https://spor.ema.europa.eu/lists/220000000000
        l: https://spor.ema.europa.eu/lists/220000000000
      code:
        v: 220000000001
      display:
        v: Full name
  part:
    part:
      v: Tegretol
  part:
    part:
      v: Carbamazepine
  part:
    part:
      v: 200 mg
  part:
    part:
      v: tablets

http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/mid-2f37d696067eeb6daf1111cfc3272672
type: ManufacturedItemDefinition
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi
    l: ManufacturedItemDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ManufacturedItemDefinition mid-2f37d696067eeb6daf1111cfc3272672 Profile: ManufacturedItemDefinition (ePI) identifier: https://spor.ema.europa.eu/pmswi/39955 (use: official, ) status: Active manufacturedDoseForm: Film-coated tablet unitOfPresentation: Tablet
identifier:
  use:
    v: official
  system:
    v: https://spor.ema.europa.eu/pmswi
    l: pmswi
  value:
    v: 39955
status:
  v: active
manufactured dose form:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi/
      l: rmswi
    code:
      v: 100000073665
    display:
      v: Film-coated tablet
unit of presentation:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi
      l: rmswi
    code:
      v: 200000002152
    display:
      v: Tablet

http://snomed.info/id/31681005
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 31681005
display:
  v: Trigeminal neuralgia (disorder)

system:
  v: https://icpc2.icd.com/
  l: icpc2.icd.com
code:
  v: W78
display:
  v: Pregnancy

http://snomed.info/id/69840006
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 69840006
display:
  v: Normal breast feeding (finding)

system:
  v: https://gsrs.ncats.nih.gov/ginas/app/beta
  l: beta
code:
  v: XK4IUX8MNB
display:
  v: Hypericum perforatum L.

system:
  v: https://gsrs.ncats.nih.gov/ginas/app/beta
  l: beta
code:
  v: 8GB79LOJ07
display:
  v: bictegravir

v: 100000155538

v: 100000155538

v: unavailable

v: 100000155538

v: 100000155538

v: 100000155538

v: 100000155538

v: Tegretol Tablets do not usually cause problems, but like all medicines, they can sometimes cause side effects. Some side effects can be serious Stop taking Tegretol Tablets and tell your doctor straight away if you notice: Serious skin reactions such as rash, red skin, blistering of the lips, eyes or mouth, or skin peeling accompanied by fever. These reactions may be more frequent in patients of Chinese or Thai origin Mouth ulcers or unexplained bruising or bleeding Sore throat or high temperature, or both Yellowing of your skin or the whites of your eyes Swollen ankles, feet or lower legs Any signs of nervous illness or confusion Pain in your joints and muscles, a rash across the bridge of the nose and cheeks and problems with breathing (these may be the signs of a rare reaction known as lupus erythematosus) Fever, skin rash, joint pain, and abnormalities in blood and liver function tests (these may be the signs of a multi-organ sensitivity disorder) Bronchospasm with wheezing and coughing, difficulty in breathing, feeling faint, rash, itching or facial swelling (these may be the signs of a severe allergic reaction) Pain in the area near the stomach You experience a fall due to dizziness, drowsiness, decrease in blood pressure, confusion. The side effects listed below have also been reported: Very common (may affect more than 1 in 10 people): Leucopenia (a reduced number of the cells which fight infection making it easier to catch infections); dizziness and tiredness; feeling unsteady or finding it difficult to control movements; feeling or being sick; changes in liver enzyme levels (usually without any symptoms); skin reactions which may be severe. Common (may affect up to 1 in 10 people): Changes in the blood including an increased tendency to bruise or bleed; fluid retention and swelling; weight increase; low sodium in the blood which might result in confusion; headache; double or blurred vision; dry mouth. Uncommon (may affect up to 1 in 100 people): Abnormal i…

title:
  v: 5. How to store Tegretol 200 mg Tablets
code:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi/
      l: rmswi
    code:
      v: 100000155538
  text:
    v: 5. How to store Tegretol 200 mg Tablets
text:
  status:
    v: additional
  div:
    v: Do not store above 25°C. Store in the original package in order to protect from moisture. Keep out of the sight and reach of children. Do not take Tegretol Tablets after the expiry date which is printed on the outside of the pack. If your doctor tells you to stop taking the tablets, please take any unused tablets back to your pharmacist to be destroyed. Do not throw them away with your normal household water or waste. This will help to protect the environment.

title:
  v: 6. Contents of the pack and other information
code:
  coding:
    system:
      v: https://spor.ema.europa.eu/rmswi/
      l: rmswi
    code:
      v: 100000155538
  text:
    v: 6. Contents of the pack and other information
text:
  status:
    v: additional
  div:
    v: The tablets come in three strengths containing either 100, 200 or 400 mg of the active ingredient carbamazepine. The tablets also contain the inactive ingredients silicon dioxide, microcrystalline cellulose, magnesium stearate and sodium carboxymethylcellulose. Tegretol 100 Tablets are round, white tablets with one side impressed “GEIGY”, the other “B/W” and a score line. Tegretol 200 Tablets are round, white tablets with one side impressed “CG”, the other “G/K” and a score line. The 100 mg and 200 mg tablets come in blister packs of 84. Tegretol 400 mg Tablets are rod-shaped, white tablets with CG/CG on one side and LR/LR on the other. Both sides have a score line. The 400 mg tablets come in blister packs of 56. Marketing Authorisation Holder: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom. Manufacturer: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom and Novartis Farma S.p.A., Via Provinciale Schito. 131, 80058 Torre Annunziata (NA), Italy. This leaflet was last revised in 11/2023. If you would like any more information, or would like the leaflet in a different format, please contact Medical Information at Novartis Pharmaceuticals UK Ltd, telephone number 01276 698370. TEGRETOL is a registered trade mark Copyright Novartis Pharmaceuticals UK Limited

v: 33CM23913M

v: CARBAMAZEPINE

v: ACTIB

v: active ingredient - basis of strength

v: 70097M6I30

v: Magnesium stearate

v: 05JZI7B19X

v: CARBOXYMETHYLCELLULOSE

v: 100000109093

v: Human

v: 100000073496

v: Blister

v: 200000003222

v: PolyVinyl Chloride

v: 220000000002

v: Invented name part

v: 220000000003

v: Scientific name part

v: 220000000004

v: Strength part

v: 220000000005

v: Pharmaceutical dose form part

v: urn:iso:std:iso:3166
l: 3166

v: ES

v: Spain

v: urn:iso:std:iso:3166
l: 3166

v: ES

v: Spain

v: urn:ietf:bcp:47
l: 47

v: en

v: English